At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 272 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 3 clinical trial evaluating Nivolumab and Docetaxel for Squamous Cell Non-small Cell Lung Cancer. Completed, enrolled 272 participants across 127 sites in 21 countries.
Detailed Summary
The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Non-small Cell Lung Cancer
CountriesArgentina, Australia, Austria, Canada, Chile, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Netherlands, Norway, Peru, Poland, Romania, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartOct 2012
Primary CompletionNov 2014
Study CompletionAug 2021
TodayJul 2026
First PostedJul 17, 2012
Enrollment StartOct 16, 2012
Primary CompletionNov 17, 2014
Study CompletionAug 16, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.0 years ago
Interventions
Nivolumabbiological
Docetaxeldrug